<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="uk">
		<id>http://istoriya.soippo.edu.ua/index.php?action=history&amp;feed=atom&amp;title=One_Overlooked_Answer_For_Fleroxacin</id>
		<title>One Overlooked Answer For Fleroxacin - Історія редагувань</title>
		<link rel="self" type="application/atom+xml" href="http://istoriya.soippo.edu.ua/index.php?action=history&amp;feed=atom&amp;title=One_Overlooked_Answer_For_Fleroxacin"/>
		<link rel="alternate" type="text/html" href="http://istoriya.soippo.edu.ua/index.php?title=One_Overlooked_Answer_For_Fleroxacin&amp;action=history"/>
		<updated>2026-06-24T14:09:23Z</updated>
		<subtitle>Історія редагувань цієї сторінки в вікі</subtitle>
		<generator>MediaWiki 1.24.1</generator>

	<entry>
		<id>http://istoriya.soippo.edu.ua/index.php?title=One_Overlooked_Answer_For_Fleroxacin&amp;diff=161325&amp;oldid=prev</id>
		<title>Animal13neck: Створена сторінка: 012) [10]. In one study of 18 XDR-TB patients, 60.9% had received previous treatment under DOT strategy (P?=?0.005) [21]. Eker et?al. and Murase et?al. also rep...</title>
		<link rel="alternate" type="text/html" href="http://istoriya.soippo.edu.ua/index.php?title=One_Overlooked_Answer_For_Fleroxacin&amp;diff=161325&amp;oldid=prev"/>
				<updated>2017-04-05T10:44:40Z</updated>
		
		<summary type="html">&lt;p&gt;Створена сторінка: 012) [10]. In one study of 18 XDR-TB patients, 60.9% had received previous treatment under DOT strategy (P?=?0.005) [21]. Eker et?al. and Murase et?al. also rep...&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Нова сторінка&lt;/b&gt;&lt;/p&gt;&lt;div&gt;012) [10]. In one study of 18 XDR-TB patients, 60.9% had received previous treatment under DOT strategy (P?=?0.005) [21]. Eker et?al. and Murase et?al. also reported one case with previous TB treatment under DOT [11, 20], and Shah et?al. also reported 28 and 30 patients under complete or partial DOT, respectively [9]. In other case report from Burkina Faso, patient one had DOT during the first 2 months of standard therapy, and patient two had previous diagnosis of MDR-TB and had 13 months of DOT therapy of SLID [28]. In South Africa, most XDR patients had no previous TB diagnosis, [http://www.selleckchem.com/products/NVP-AUY922.html Luminespib] but it may reflect lack of reporting or high chances of nosocomial transmission [10]. In another study conducted in Tugela Ferry, 69% of patients had previous TB treatment, with 56% on the past year. More than half of the patients (57%) had been hospitalized in the previous 2 years [7]. Many [https://en.wikipedia.org/wiki/Fleroxacin Fleroxacin] potential factors might contribute to treatment failure, the most relevant being male gender and HIV coinfection [11]. Reported factors for treatment non-compliance among XDR-TB patients were alcoholism (10.1%), drug addiction (42%) or both (47.8%) [34]. The term pre-XDR-TB has been introduced recently, and is defined as resistance to rifampicin, isoniazid and either to a fluoroquinolone or a SLID [21]. A higher proportion of such patients were found in South Africa [26, 35]. Accordingly to Kim, 11.3% (n?=?159) had ofloxacin-resistant pre-XDR-TB, and 8.3% (n?=?117) had SLID-resistant pre-XDR-TB. A previous history of treatment with SLID was more common in patients with XDR-TB (35.6%) and ofloxacin-resistant pre-XDR-TB (32%), P?[http://www.selleckchem.com/products/RO4929097.html RO4929097 research buy] At least two previous TB treatments were more common in patients with XDR-TB (47.7%), ofloxacin-resistant pre-XDR-TB (38.4%) and SLID-resistant pre-XDR-TB (27%) than in other forms of MDR-TB (24.9%), P?&lt;/div&gt;</summary>
		<author><name>Animal13neck</name></author>	</entry>

	</feed>